@article{3118509,
    title = "Attainment of Inactive Disease Following Discontinuation of Adalimumab Monotherapy in Patients with Enthesitis-Related Arthritis: A Real-Life, Dual-Center Experience",
    author = "Papailiou, S. and Dasoula, F. and Tsolia, M.N. and Maritsi, D.N.",
    journal = "JCR-JOURNAL OF CLINICAL RHEUMATOLOGY",
    year = "2022",
    volume = "28",
    number = "2",
    pages = "E616-E618",
    publisher = "Lippincott Williams and Wilkins",
    doi = "10.1097/RHU.0000000000001762",
    keywords = "adalimumab;  antirheumatic agent, human;  juvenile rheumatoid arthritis;  treatment outcome, Adalimumab;  Antirheumatic Agents;  Arthritis, Juvenile;  Humans;  Treatment Outcome",
    abstract = "The optimum duration of treatment in patients with juvenile idiopathic arthritis (JIA), including enthesitis-related arthritis (ERA), is an area of pivotal concern for both parents and physicians. Novel medicines have managed to achieve remission of this otherwise debilitating condition1; however, issues regarding the duration and the best timing for termination of therapy endure.2 Enthesitis-related arthritis remains one of the most challenging JIA subtypes in terms of drug management and withdrawal. We report the results of a medical records review study aiming to describe the long-term outcome of children with a specific subcategory of ERA, solely treated with a tumor necrosis factor inhibitor (TNFi) (adalimumab [ADA]), in whom treatment was discontinued, following sustained clinical remission, and to identify potential relapse-associated risk factors. © 2022 Lippincott Williams and Wilkins. All rights reserved."
}